Stroke (Ischemic and Hemorrhagic)
Stroke is the 3rd leading cause of death in America (#1 in Portugal and in Asia) and the primary cause of adult disability. Stroke accounts for 1 of every 18 deaths in the US. About 795,000 Americans suffer a new or recurrent stroke each year. In 2008, the estimated stroke-related medical costs were ~$65.5 billion.
Stroke Research at CTRND
Dr. Sylvain Doré:
The goal of Sylvain Doré’s team effort is to discover new effective mechanisms that limit neuronal dysfunction associated with ischemic and hemorrhagic Stroke, Alzheimer disease (AD), aging, brain trauma, and various other neurological disorders. The overall goal is to slow down the progression of the disease, and ultimately stop it. To do so, the aim is to limit neuron death (apoptosis and necrosis) resulting from acute and/or chronic neurodegenerative conditions, re-establish normal cerebral blood flow, limit inflammation, and restore regular cellular functions. Using a variety of in vitro and in vivo preclinical models, several new hypotheses and potential therapies are being investigated and developed.
Here is our working chronologic model that with appropriate funding helps us to test the efficacy and mechanisms of action of various therapies being developed targeting ischemic and hemorrhagic stroke and also vascular dementia, aged-related cognitive disorders, Alzheimer’s disease and other acute and/or chronic neurological disorders.